BETA.05 Recipient: MidUrine Female

Female incontinence makes it difficult to collect high-quality urine samples. Poor and contaminated sample quality often results in misdiagnosed urinary tract infections (UTIs), leading to the unnecessary use of antibiotics.

MidUrine Female, the first leave-on urine sample collector for women, improves sample quality and diagnostic accuracy.

Clinical Impact

·      Streamlined clinical workflows

·      Higher quality urine samples for faster, more accurate treatment

·      Less-invasive procedures, improved patient comfort and dignity

·      Reduced antibiotic use, lowering the risk of resistance

·      Cost saving from fewer tests and antibiotics, and less time per patient 

The BETA.HEALTH 'Accelerator Programme'

During the project's BETA.HEALTH 'accelerator programme', the team aimed to validate MidUrine Female against the standard catherisation procedure for incontinent patients requiring evaluation for UTIs.

In collaboration with the Department of Urology at Aarhus University Hospital and Trøjborg Lægehus, the team gathered key insights to refine their prototype. With a clear value proposition and a new prototype in hand, they finalised plans for validation and feasibility studies­ – and initiated both.

Towards the end of the accelerator phase, the team began discussions with a possible industry partner . They've ­exited the programme well-prepared for the next steps in their innovation journey, with a polished slide deck and solid pitch developed with guidance from BETA.HEALTH's innovation consultants.

Reflecting on his experience in the programme, the project's co-applicant, Morten Charles said, 'It's been rewarding and incredibly educational to be a part of the BETA.HEALTH programme. We’ve gained valuable insights and constructive sparring, which has enabled us to significantly advance our project. We've also appreciated the opportunities to network with the other teams.'

Next Steps

Building on the momentum created during the project's accelerator phase, the team is finalising their validation against standard procedures and finalising feasibility and implementation studies at two nursing homes.

If the results are positive, they'll pursue investment plans and continue their dialogue with the possible industry partner. The current trajectory is for MidUrine Female to reach the market and clinical implementation in 2026!

The Team

Charlotte Graugaard-Jensen: MD, PhD, Associate Professor; Urology Dept., Aarhus University Hospital

Morten H. Charles: General Practitioner, Trøjborg Lægehus; Aarhus Medical Project Leader